New pill takes on advanced cancers in early trial
NCT ID NCT07339748
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental pill called ZL-85FA in people with advanced solid tumors (breast, ovarian, fallopian tube, primary peritoneal, or prostate cancer) that have not responded to standard treatments. The trial has two phases: first, finding a safe dose, then checking for early signs of tumor shrinkage. About 51 participants will take the pill once daily, and researchers will monitor safety and how well the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZL-85FA tablets (an experimental oral drug)
What this could lead to
If successful, this could point toward a new oral treatment option for certain advanced cancers like breast, ovarian, or prostate cancer.
What could go wrong
This is an early-phase trial with only 51 participants, so it is too soon to know if the drug works. Side effects are unknown, and many early cancer drugs fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital Of Anhui Medical University
Hefei, Anhui, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact